

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Olson, Gary L. *et al.*

Serial No.: 09/972772

Filed: October 5, 2001

For: *Therapeutic Agents and Methods of Use Thereof
for the Modulation of Angiogenesis*

Attorney Docket No.: PPI-106CP

Group Art Unit: 1653

Examiner: Russel, J.

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

2/3/04

Date of Signature and of Mail Deposit

By:

Jane E. Remillard, Esq.
Registration No. 38,872
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form SB-08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration.

The present application is a Continuation-in-Part Application of U.S. Serial No. 09/704251, filed November 1, 2000 (Atty. Docket No. PPI-106). The majority of the references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application and, in accordance with 37 CFR §1.98(d), copies of references A1-C1, C3, C5-C12 are not enclosed, but will be provided upon request. Reference ID Nos. C2 and C4 were cited in an International Search Report during the prosecution of PCT/US03/13623 dated November 13, 2003

Adjustment date: 03/17/2004 SDIRETA1
02/11/2004 MMHbii 00000009 120080 09972772
01 FC:1606 160.00 CR

02/11/2004 MMHbii 09972772
00000009 120080 00000000
160.00 CR
01 FC:1606

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Olson, Gary L. et al.

Serial No.: 09/972772

Filed: October 5, 2001

For: *Therapeutic Agents and Methods of Use Thereof
for the Modulation of Angiogenesis*

Attorney Docket No.: PPI-106CP

STATUS: FILED
8PMA.DR

Group Art Unit: 1653

2004 MAR -9 AM 8:50
Examiner: Russel, J.

Commissioner for Patents
Washington, D.C. 20231
Attn: Refund Section
Accounting Division, Office of Finance

REQUEST FOR REFUND

Dear Sir:

Applicant hereby requests a refund of the Information Disclosure Statement submission fee in the amount of \$180.00 charged to our Deposit Order Account on February 11, 2004. Applicant filed an Information Disclosure Statement on January 27, 2003 under 37 C.F.R. §1.97, which was received by the Patent Office on February 3, 2004. As of yet, an Office Action on the merits has not been received by our office. Therefore, no fee should be charged. A copy of the Information Disclosure Statement is enclosed.

Please credit this amount to our Deposit Account No. 12-0080. For this purpose, we enclose a duplicate copy of this letter.


Certificate of First Class Mailing (37 C.F.R. 1.8(a))
I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231
Attn: Refund Section, Accounting Division, Office of Finance, on:

3/5/04

Date

Jane E. Remillard, Esq., Registration No. 38,872

Respectfully submitted,


Jane E. Remillard, Esq.

Registration No. 38,872

Attorney for Applicants

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, MA 02109

(617) 227-7400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

STATUS AND ENTRY
BRANCH

16 MAR -9 AM 8:50

In re the application of: Olson, Gary L. et al.

Serial No.: 09/972772

Filed: October 5, 2001

For: *Therapeutic Agents and Methods of Use Thereof
for the Modulation of Angiogenesis*

Attorney Docket No.: PPI-106CP

Group Art Unit: 1653

Examiner: Russel, J.

RECEIVED

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

2/3/04

Date of Signature and of Mail Deposit

By:


Jane E. Remillard, Esq.
Registration No. 38,872
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form SB-08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration.

The present application is a Continuation-in-Part Application of U.S. Serial No. 09/704251, filed November 1, 2000 (Atty. Docket No. PPI-106). The majority of the references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application and, in accordance with 37 CFR §1.98(d), copies of references A1-C1, C3, C5-C12 are not enclosed, but will be provided upon request. Reference ID Nos. C2 and C4 were cited in an International Search Report during the prosecution of PCT/US03/13623 dated November 13, 2003

STATUS AND ENTRY
BROWNS


which corresponds to the above referenced application. A copy of the report and two cited publications are enclosed.

TUE MAR -9 11 8:50

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Jane E. Remillard, Esq.
Registration No. 38,872
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: 2/3/04

GAD/JER/MCL/JMS/alf
Enclosures